GH-Deficient Survivors of Childhood Cancer: GH Replacement during Adult Life
R. D. Murray,
K. H. Darzy,
H. K. Gleeson and
S. M. Shalet
Department of Endocrinology, Christie Hospital, Manchester, M20 4BX, United Kingdom
Address all correspondence and requests for reprints to: Prof. S. M. Shalet, Department of Endocrinology, Christie Hospital NHS Trust, Wilmslow Road, Manchester, M20 4BX, United Kingdom.
Childhood survivors of cancer are prone to a number of adversesequelae related to the therapeutic interventions undertakento achieve remission. The endocrine system is frequently affected;hypothalamo-pituitary dysfunction, in particular GH deficiency,is common after cranial irradiation. It is unclear to what extentGH deficiency contributes to the abnormalities observed in adultsurvivors of childhood cancer, and whether GH replacement reversesthese anomalies. We compared 27 GH-deficient survivors of childhoodcancer with 27 adult age- and sex-matched controls and wenton to replace GH in the patient group to determine whether GHresulted in improvements of the baseline abnormalities.
The GH-deficient survivors of childhood cancer had an adverselipid profile (total cholesterol, 5.4 vs. 4.6 mM, P = 0.004;high-density lipoprotein cholesterol, 1.05 vs. 1.6 mM, P <0.001; and triglycerides, 1.3 vs. 1.0 mM, P < 0.001) andwere osteopenic (lumbar spine z-score, -1.53 vs. -0.31 SD score,P < 0.001; femoral neck z-score, -1.23 vs. -0.27 SD score,P = 0.02); additionally, the female subgroup had an increasedpercentage body fat (43.6 vs. 32.8%, P = 0.016). In keepingwith the selection criterion, quality of life in the patientcohort, relative to the healthy controls, was severely impaired[adult GH-deficiency assessment (AGHDA), 15.5 (range, 825)vs. 1 (range, 019), P < 0.0001; psychological generalwell-being schedule, 67.5 (range, 1886) vs. 89.0 (range,51104), P < 0.0001].
After 12 months of GH replacement, small (but significant) improvementswere observed in body composition in the male subgroup (waist-hipratio, 0.871 vs. 0.863, P < 0.05); and in the female cohort,total cholesterol (6.0 vs. 5.2 mM, P = 0.01) and triglyceride(2.1 vs. 1.4 mM, P = 0.01) levels fell. Bone mineral densityimproved in only one of the four sites studied (ultradistalradius, -1.21 vs. -1.09, P = 0.048) after a median durationof GH therapy of 18 months. Quality of life improved dramaticallyby 3 months (AGHDA, 15.5 vs. 10.0, P < 0.001), and the improvementwas maintained at 12 months (AGHDA, 15.5 vs. 9.0, P < 0.001).Importantly, there was no clinical suggestion of tumor recurrenceduring the 12 months of GH replacement.
The minor improvements observed in body composition, the lipidprofile, and bone mineral density in GH-deficient adult survivorsof childhood cancer after 1218 months of physiologicalGH replacement suggest that GH deficiency may not be the majoretiological factor in their pathogenesis; the converse seemsto be true for the quality of life status of these individuals.We propose that, as in patients with hypopituitarism causedby pituitary disease, the main indication for GH replacementin GH-deficient survivors of childhood cancer should be severeimpairment of quality of life.
Abbreviations: AGHDA, Adult GH-deficiency assessment; ALL, acutelymphoblastic leukemia; BMD, bone mineral density; BMI, bodymass index; DXA, dual-energy x-ray absorptiometry; HbA1C, hemoglobin-A1C;HDL, high-density lipoprotein; LDL, low-density lipoprotein;PGWB, psychological general well-being schedule; SDS, SD score;TC, total cholesterol; TG, triglyceride; WHR, waist to hip ratio.
This article has been cited by other articles:
D Maiter, R Abs, G Johannsson, M Scanlon, P J Jonsson, P Wilton, and M Koltowska-Haggstrom Baseline characteristics and response to GH replacement of hypopituitary patients previously irradiated for pituitary adenoma or craniopharyngioma: data from the Pfizer International Metabolic Database.
Eur. J. Endocrinol.,
August 1, 2006;
155(2):
253 - 260.
[Abstract][Full Text][PDF]
C. Follin, U. Thilen, B. Ahren, and E. M. Erfurth Improvement in Cardiac Systolic Function and Reduced Prevalence of Metabolic Syndrome after Two Years of Growth Hormone (GH) Treatment in GH-Deficient Adult Survivors of Childhood-Onset Acute Lymphoblastic Leukemia
J. Clin. Endocrinol. Metab.,
May 1, 2006;
91(5):
1872 - 1875.
[Abstract][Full Text][PDF]
S. E. Lipshultz, S. A. Vlach, S. R. Lipsitz, S. E. Sallan, M. L. Schwartz, and S. D. Colan Cardiac Changes Associated With Growth Hormone Therapy Among Children Treated With Anthracyclines
Pediatrics,
June 1, 2005;
115(6):
1613 - 1622.
[Abstract][Full Text][PDF]
A. Mukherjee, S. Tolhurst-Cleaver, W. D. J. Ryder, L. Smethurst, and S. M. Shalet The Characteristics of Quality of Life Impairment in Adult Growth Hormone (GH)-Deficient Survivors of Cancer and Their Response to GH Replacement Therapy
J. Clin. Endocrinol. Metab.,
March 1, 2005;
90(3):
1542 - 1549.
[Abstract][Full Text][PDF]
H K Gleeson and S M Shalet The impact of cancer therapy on the endocrine system in survivors of childhood brain tumours
Endocr. Relat. Cancer,
December 1, 2004;
11(4):
589 - 602.
[Abstract][Full Text][PDF]
H. K. Gleeson, R. Stoeter, A. L. Ogilvy-Stuart, H. R. Gattamaneni, B. M. Brennan, and S. M. Shalet Improvements in Final Height Over 25 Years in Growth Hormone (GH)-Deficient Childhood Survivors of Brain Tumors Receiving GH Replacement
J. Clin. Endocrinol. Metab.,
August 1, 2003;
88(8):
3682 - 3689.
[Abstract][Full Text][PDF]
M. Misra, L. A Soyka, K. K Miller, S. Grinspoon, L. L Levitsky, and A. Klibanski Regional body composition in adolescents with anorexia nervosa and changes with weight recovery
Am. J. Clinical Nutrition,
June 1, 2003;
77(6):
1361 - 1367.
[Abstract][Full Text][PDF]